TABLE 5.
Major clusters of co-cited references.
| Cluster ID | Size | Silhouette | Mean (year) | Top terms (LSI) | Top terms (LLR) | Terms (MI) |
|---|---|---|---|---|---|---|
| 0 | 96 | 0.842 | 2015 | Berberine; ERK1/2; and glioma | Invasion; migration; and glioma | Triptolide; RT-R breast cancer cells; and chemoprotective agents |
| 1 | 86 | 0.884 | 2008 | Breast cancer; signaling pathways; and leukemia | Daxx; side population; and invasiveness | Daxx; side population; and invasiveness |
| 2 | 85 | 0.935 | 2003 | Berberine; thermodynamics; and non-cooperative binding | Interleukin-1 beta; ARPE-19 cells; and interleukin-8 | Berberine; berberine interleukin-1 beta; and cooperative binding |
| 3 | 78 | 0.887 | 2016 | Berberine; carrier-free; and gram-scale | Photodynamic therapy; and epithelial–mesenchymal transition | Transforming growth factor; rat; and reverse pharmacophore mapping |
| 4 | 70 | 0.907 | 2017 | Berberine; doxorubicin; and neurotoxicity | Non-small-cell lung cancer; liquid crystalline nanoparticles; and neurotoxicity | Demethyleneberberine; modern science; and top2b |
| 5 | 69 | 0.95 | 2006 | Berberine; apoptosis; and ATF3 | P53; apoptosis; and Coscinium fenstratum | Human liver microsomes; anti-metastasis; and Tinospora cordifolia |
| 6 | 59 | 0.878 | 2012 | Berberine; IL-8; and adhesion | Prostate cancer; evodiamine; and epigenetics | Interleukin-8; traditional Chinese medicine; and gemcitabine |
| 7 | 51 | 0.914 | 2012 | Tumor necrosis factor-alpha; brain inflammation; and interleukin-1 beta | TNF-α; lipopolysaccharide; and NF-κB | Berberine intestinal mucosal barrier; interleukin-1; and interleukin-6 |
| 8 | 45 | 0.903 | 2011 | Cervical cancer; gastrointestinal disorders; and antitumor | Antioxidant; piperazine; and cervical cancer | RNA triplex; g-quadruplexes; and catenin |
| 9 | 45 | 0.971 | 2000 | Human topoisomerase; anti-cancer drugs; and structure-based molecular modeling | Structure-based molecular modeling; interleukin-12; p38 MAPK; and anti-cancer drugs | Berberine; apoptosis; and structure-based molecular modeling |
| 10 | 43 | 0.994 | 2000 | Anticancer activity; anticancer effects; and colorectal cancer | Herb; colon 26/clone 20 cells; and pancreatic cancer | Berberine; apoptosis; and colon 26/clone 20 cells |
| 11 | 30 | 0.97 | 2017 | Gut microbiota; pharmacokinetic study; and amino acid | Gut microbiota; atherosclerosis; and metabolomics | Metabolomics; fecal metabolites; and functional nano-vector |
| 12 | 22 | 0.942 | 2007 | Berberine; barrier function; plant alkaloid; and lipid mediators | Atherogenesis; anti-microbial; and acute intestinal symptoms | Berberine; atherogenesis; and anti-microbial |
| 13 | 16 | 0.997 | 2017 | Lung cancer; inhalable nanocomposites; and drug nanosuspension | Lung cancer; lactoferrin targeting; and drug nanosuspension | Berberine; apoptosis; and lactoferrin targeting |
| 14 | 13 | 0.957 | 2010 | Replication stress; H2AX phosphorylation; DNA damage; and ribosomal protein S6 phosphorylation | Rapamycin; replication stress; and salicylate | Berberine; salicylate; and ribosomal protein S6 phosphorylation |
| 15 | 10 | 0.995 | 2016 | Alkylated; HeLa cell; and carbohydrate | Carbohydrate; alkylated; and anticancer | Berberine; carbohydrate; and alkylated |
| 17 | 8 | 0.983 | 2014 | Kainic acid; status epilepticus; and oxidative stress | Natural toxin; chronic unpredictable mild stress; and temporal lobe epilepsy | Berberine; natural toxin; and chronic unpredictable mild stress |
| 18 | 7 | 0.998 | 2004 | Berberine; ATF3; and apoptosis | ATF3; nag-1; p53; and apoptosis | Berberine; apoptosis; cancer; and breast cancer |
| 20 | 4 | 0.99 | 2011 | AMPK; aspirin; and berberine | Aspirin; metformin; AMPK; and resveratrol | Berberine; apoptosis; and cancer |